(E)-2-CYANO-3-(4-HYDROXY-3,5-DIISOPROPYLPHENYL)ACRYLAMIDE, 95%, 5mg

8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrobromide, 95.0%, 1g

4-Fluoro-2-methyl-3-nitrobenzoic acid, 97.0%, 5g

Sample vials with short thread ND9 Vial kit, HPLC-certified, Clear glass, with labelling space, 1 Set

1-[2-(2-fluorophenoxy)ethyl]-1H-indole-3-carbaldehyde, 95.0%, 5g

4-Methoxy-2-(1H-pyrazol-1-yl)benzonitrile>95.0%(GC)1g

TERT-BUTYL 3-(1-(((BENZYLOXY)CARBONYL)AMINO)-2-METHOXY-2-OXOETHYL)AZETIDINE-1-CARBOXYLATE, 95.0%, 5g

(S)-N-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)-propionamide, 97.0%, 1g

(S)-2-Amino-3-(5-fluoro-1H-indol-3-yl)propanoic acid, 95.0%, 10g

4-Amino-3-nitrobenzotrifluoride, 98.0%, 1g

Fmoc-Abu-OH, 96.0%, 5g

5-Bromo-4-chloro-2-methylpyridine, 95.0%, 250mg

2-(4,4-Difluorocyclohexyl)acetic acid, 95.0%, 5g